Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease

Area of Science:

• Neuroscience
• Radiochemistry
• Clinical Neurology

Background:

• Smoking is linked to lower Parkinson's disease (PD) incidence, suggesting nicotine's neuroprotective potential.
• Postmortem studies indicate reduced cerebral nicotinic acetylcholine receptors (nAChRs) in PD patients.
• In vivo imaging is needed to confirm nAChR changes in PD and their relation to disease progression.

Purpose of the Study:

• To quantify nAChR availability in non-demented PD patients using in vivo positron emission tomography (PET).
• To investigate the correlation between nAChR density and PD severity, assessed by clinical scores and dopaminergic function.
• To compare nAChR availability in PD patients with healthy controls.

Main Methods:

• PET imaging was performed on 13 non-demented PD patients and 6 healthy controls.
• Two PET scans were utilized: one for dopaminergic function (6-[18F]fluoro-L-DOPA) and another for nAChRs (2-[18F]fluoro-A-85380).
• Regions-of-interest and voxel-based analyses compared 2-[18F]fluoro-A-85380 distribution volumes (DVs) between groups.

Main Results:

• PD patients exhibited a significant decrease in 2-[18F]fluoro-A-85380 DV in the striatum (-10%) and substantia nigra (-14.9%) compared to controls.
• No significant correlation was observed between nAChR DV and clinical PD severity scores.
• No significant correlation was found between nAChR DV and PET-measured striatal dopaminergic function.

Conclusions:

• This in vivo study confirms reduced nAChR availability in the striatum and substantia nigra of PD patients.
• The observed decrease in nAChRs does not correlate with clinical or dopaminergic markers of PD severity in this cohort.
• Further research is needed to elucidate the role of nAChRs in PD pathogenesis and progression.